Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CYP1A2 · 1 trial · 1 indication
To assess the effect of AZD1775 on the PK of probe substrates for CYP1A2 (caffeine), CYP2C19 (omeprazole), and CYP3A (midazolam)
To assess the effect of AZD1775 on the PK of probe substrates for CYP1A2 (caffeine), CYP2C19 (omeprazole), and CYP3A (midazolam)
To assess the effect of AZD1775 on the PK of probe substrates for CYP1A2 (caffeine), CYP2C19 (omeprazole), and CYP3A (midazolam)
To assess the effect on QT interval corrected for heart rate (QTc) following multiple oral doses of AZD1775
| Arm | Type | Description |
|---|---|---|
| Wee-1 kinase inhibitor AZD1775 | EXPERIMENTAL | To evaluate the effect of multiple doses of AZD1775 on the PK of substrates for CYP3A (midazolam), CYP2C19 (omeprazole), CYP1A2 (caffeine) and to evaluate the effect of multiple doses of AZD1775 on QT interval |
| Name | Type | Description |
|---|---|---|
| CYP1A2 (caffeine) | DRUG | In Part A, Period 1, patients will be administered a 3 drug cocktail of caffeine, omeprazole and midazolam on Day -8 followed by a washout period of at least 7 but no more than 14 days. In Part A, Period 2, AZD1775 capsules will be administered orally, 225 mg bid, until steady state for 2.5 days (total of 5 doses) and administered together with the cocktail on the morning of Day 3. |
| CYP2C19 (omeprazole) | DRUG | In Part A, Period 1, patients will be administered a 3 drug cocktail of caffeine, omeprazole and midazolam on Day -8 followed by a washout period of at least 7 but no more than 14 days. In Part A, Period 2, AZD1775 capsules will be administered orally, 225 mg bid, until steady state for 2.5 days (total of 5 doses) and administered together with the cocktail on the morning of Day 3. |
| CYP3A (midazolam) | DRUG | In Part A, Period 1, patients will be administered a 3 drug cocktail of caffeine, omeprazole and midazolam on Day -8 followed by a washout period of at least 7 but no more than 14 days. In Part A, Period 2, AZD1775 capsules will be administered orally, 225 mg bid, until steady state for 2.5 days (total of 5 doses) and administered together with the cocktail on the morning of Day 3. |
| Kytril (granisetron) | DRUG | Patients should be administered Kytril (granisetron) 1 mg orally, under fasted conditions (-2 to 2 hours away from meals), 30 minutes prior to administration of the AZD1775 capsules with a small amount of water. |
| Wee-1 kinase inhibitor AZD1775 | DRUG | Multiple doses of 225 mg AZD1775, (3 x 75 mg, printed capsules) administered orally. The drug class of AZD1775 is Wee-1 kinase inhibitor. |
Inclusion Criteria: * Has read and understands the informed consent form (ICF) and has given written informed consent prior to any study procedures. * Histologically or cytologically documented, locally advanced or metastatic solid tumour, excluding lymphoma, for which standard therapy does not exi...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
CYP1A2 is an investigational small molecule being studied in oncology. It is being developed by AstraZeneca PLC for the treatment of solid tumours. The drug is currently in Phase 1 clinical development, with one completed trial involving 33 patients.
CYP1A2 is being studied for use in solid tumours. It is an investigational small molecule in Phase 1 clinical development. The completed trial evaluated its effects on drug metabolism and QT interval in patients with advanced cancer.
CYP1A2 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The drug is an investigational small molecule in Phase 1 clinical development for the treatment of solid tumours.
CYP1A2 is in Phase 1 clinical development. It is an investigational small molecule being studied for solid tumours. The drug has one completed Phase 1 trial, and it is not yet approved by regulatory authorities.
CYP1A2 has one completed clinical trial, NCT03333824, titled 'Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer'. This Phase 1 study enrolled 33 patients with solid tumours in the United States.
CYP1A2 is not the same as AZD1775. The clinical trial NCT03333824 evaluated the effects of AZD1775 on CYP1A2, which is a drug-metabolizing enzyme, not the investigational drug itself. CYP1A2 is the name of the enzyme being studied as a substrate in the trial.